Pacific Biosciences of California (PACB) : Traders are bullish on Pacific Biosciences of California (PACB) as it has outperformed the S&P 500 by a wide margin of 17.67% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.62%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 7.55% in the last 1 week, and is up 21.62% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 10.77% and the 50-Day Moving Average is 0.02%. Pacific Biosciences of California, Inc. has dropped 11.4% during the last 3-month period . Year-to-Date the stock performance stands at -34.88%.
Pacific Biosciences of California (NASDAQ:PACB): On Fridays trading session , Opening price of the stock was $8.53 with an intraday high of $8.63. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $8.29. However, the stock managed to close at $8.55, a loss of 0.58% for the day. On the previous day, the stock had closed at $8.6. The total traded volume of the day was 1,123,034 shares.
Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Companys Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.